<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108107</url>
  </required_header>
  <id_info>
    <org_study_id>S-20100014</org_study_id>
    <nct_id>NCT01108107</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Colon Cancer</brief_title>
  <official_title>Neoadjuvant Chemotherapy and Biological Treatment for Patients With Locally Advanced Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate

        -  the effect of preoperative combination chemotherapy in patients with locally advanced
           colon cancer with mutation in the KRAS, BRAF or PIK3CA gene

        -  the effect of preoperative combination chemotherapy in combination with biological
           treatment in patients without mutation in the KRAS, BRAF or PIK3CA gene.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.</measure>
    <time_frame>Within 1 week after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>Up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + biological treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 intravenously on day 1 of a 3-weekly cycle</description>
    <arm_group_label>Chemotherapy only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle</description>
    <arm_group_label>Chemotherapy only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 intravenously on day 1 of a 3-weekly cycle</description>
    <arm_group_label>Chemotherapy + biological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle</description>
    <arm_group_label>Chemotherapy + biological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>9 mg/kg intravenously on day 1 of a 3-weekly cycle</description>
    <arm_group_label>Chemotherapy + biological treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan

          -  Analysis of KRAS, BRAF, PIK3CA

          -  Age ≥18 år

          -  Performance status ≤ 2

          -  Hematology

               -  ANC ≥ 1.5x10^9/l. Thrombocytes ≥ 100x10^9/l.

          -  Biochemistry

               -  Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL

          -  Consent to translational research

          -  Fertile women must present a negative pregnancy test and use secure birth control
             during and 3 months after treatment.

          -  Written and orally informed consent.

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent
             disease.

          -  Peripheral neuropathy NCI grade &gt;1

          -  Other malignant disease within 5 years prior to enrollment, except basal cell squamous
             carcinoma of the skin and cervical carcinoma-in-situ

          -  Other investigational treatment within 30 days prior to treatment start

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  Bleeding tumors

          -  Hypersensitivity to one or more of the substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology, Hilleroed Hospital</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>KRAS mutation</keyword>
  <keyword>BRAF mutation</keyword>
  <keyword>PIK3CA mutation</keyword>
  <keyword>Possibly avoid chemotherapy after operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

